Wed, Apr 26, 2017
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Survey finds London’s financial status will not be affected by AIFMD

Tuesday, July 24, 2012

Beverly Chandler, Opalesque London: A survey by compliance consultants the IMS Group has revealed that the alternatives industry is uncertain as to how the arrival of The Alternative Investment Fund Managers Directive (AIFMD) will impact on investment firms.

The survey was conducted among a group of 150 delegates at an IMS briefing on AIFMD. Findings included that with a year to go before its implementation, two fifths of the survey’s respondents (41%) were still assessing whether AIFMD would cause managers to make structural changes to their organisation. Further to this, 42% of respondents to the survey expected that AIFMD would influence their marketing strategies from 2013 onwards, 29% expected little influence and 23% didn’t expect any influence.

The survey came as news was announced that the publication of the final detail of the directive, which was slated for release on 22 July 2012, had been delayed, causing further uncertainty in the investment management industry.

IMS reported other findings that included:

  • 77% of respondents think regulatory developments such as AIFMD will have little or no impact on the attraction of London as a financial hub.
  • Capital requirements (19%) and risk management (21%) were highlighted as the top areas of concern for respondents within AIFMD, followed by depositary liability (14%) and remuneration (12%).
  • The largest negative impact of AIFMD is expected to be the ability to fundraise in Europe. Ho......................

    To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Alternative asset firm YieldStreet surpasses $100m of loans funded in less than 8 quarters[more]

    Komfie Manalo, Opalesque Asia: Alternative asset investment platform YieldStreet reported that it has surpassed $100m in loans funded in less than eight quarters from accredited investors and single family offices. YieldStreet was founded by Milind Mehere and Michael Weisz. In a

  2. Investing - Investor appetite for high-growth IPOs to be tested, Apollo boosts fund's stock allowance for 'diamonds in the rough', Hedge funds uncertain over outlook for Hargreaves Lansdown[more]

    Investor appetite for high-growth IPOs to be tested From FT.com: The US listings market is poised for a busy week with deals that will test investors' appetite for high-growth - but lossmaking - companies. Eight new listings are scheduled for this week, the most since October of 2016,

  3. Hedge funds holding Puerto Rico bonds are looking at a long battle[more]

    Komfie Manalo, Opalesque Asia: Hedge funds which bought Puerto Rico's distressed debt bonds are facing the prospect of a long road ahead to recover their investments as the Caribbean island is attempting to use a U.S. Congress-approved rule that allows it to exploit a bankruptcy-like proceedings

  4. Other Voices: "Winner-take-all" dynamics and hedge fund investing[more]

    A growing stream of thinking in microeconomics is the concept of "winner-take-all" dynamics. The idea seems simple. A combination of networking economics and classic economies of scale creates situations where there are just a few dominant firms or economic agents who are able to capture significant

  5. Investing - How Chipotle's comeback attracted big data robots and value investors alike[more]

    From Forbes.com: When William Ackman's ailing hedge fund Pershing Square Capital Management bet $1 billion on shares in Chipotle Mexican Grill beginning in July 2016, the stakes couldn't have been higher. Pershing Square was reeling from what would eventually be a near $4 billion loss in drugmaker V